Translational immunotoxicology of immunomodulatory monoclonal antibodies

Publication date: Available online 19 October 2016 Source:Drug Discovery Today: Technologies Author(s): Frank R. Brennan, Andrea Kiessling While immunomodulatory monoclonal antibodies (mAbs) have a wide therapeutic potential, exaggerated immunopharmacology may drive both acute and delayed immunotoxicity. The existing tools for immunotoxicity assessment do not accurately predict the full range of immunotoxicities observed in humans. New and optimized models, assays, endpoints and biomarkers in animals and humans are required to safeguard patients and allow them access to these often transformational therapies.
Source: Drug Discovery Today: Technologies - Category: Drugs & Pharmacology Source Type: research